For patients who cannot get their cholesterol down with statins alone, one of the most powerful options has come with a needle. PCSK9 inhibitors cut LDL - the 'bad' cholesterol - by more than half, but they have been biologic drugs, self-injected every two to four weeks, and that barrier limited how many people used them. On July 16, the FDA approved the first one that comes as a daily pill [1].
The drug, Merck's Lipfendra (enlicitide), is a once-daily 20-milligram tablet, the first and only oral PCSK9 inhibitor cleared to lower LDL [1][2]. In its pivotal trial it reduced LDL cholesterol by about 56 percent compared with placebo; in a trial of patients with an inherited high-cholesterol condition, by about 59 percent - reductions in the range of the injectable versions [1].
Data
| Main trial (CORALreef Lipids) | 56 LDL-C reduction vs placebo (%) |
|---|---|
| Inherited-cholesterol trial (HeFH) | 59 LDL-C reduction vs placebo (%) |
One important limit belongs in the same breath as the numbers. This approval is based on how much the drug lowers LDL, a marker - not yet on whether it prevents heart attacks and strokes [1]. The cardiovascular-outcomes trial that would answer that is still under way [1]. Lowering LDL this much is strongly expected to help, on everything known about the class, but 'expected to' is not the same as 'shown to,' and the outcomes data are not in [1].
What the approval changes is access. A pill removes the needle - the practical obstacle that kept a potent cholesterol treatment from many of the statin-inadequate patients who could benefit, including those with familial hypercholesterolemia [1]. The open question is the one that follows most new drugs: what it will cost, and whether insurers will cover a branded daily pill against cheap generic statins [1]. The record is a real advance with an asterisk - the first oral drug in a powerful class, potent on the number it targets, still waiting to prove it changes the outcomes that number stands for [1].
